Lercatio (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels on arterial smooth‑muscle cells. This inhibition prevents calcium‑driven contraction, causing the blood vessels to relax and widen (vasodilation). The resulting drop in peripheral resistance lowers both systolic and diastolic blood pressure.

The appropriate dose of Lercatio is determined by the prescribing healthcare professional based on the individual’s blood pressure, response to therapy, and any co‑existing medical conditions. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of lercanidipine in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To request Lercatio, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lercatio belongs to the dihydropyridine calcium‑channel blocker class, which primarily causes arterial vasodilation. Compared with ACE inhibitors or beta‑blockers, it has a lower incidence of cough but may be more likely to cause peripheral edema. Choice of therapy depends on patient profile, comorbidities, and tolerability.

Lercatio should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, heat, and direct sunlight. Do not store in bathrooms or near kitchen appliances that generate heat.

Lercatio is taken orally, usually once daily, with or without food. Swallow the tablet whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and avoid missing doses.

Serious risks include severe hypotension, which can cause fainting or shock, and rare hepatic dysfunction manifested by elevated liver enzymes. Allergic reactions such as rash, angioedema, or anaphylaxis may also occur. Any sudden or severe symptoms should prompt immediate medical evaluation.

Lercatio is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation. It should also be avoided in individuals with severe aortic stenosis, cardiogenic shock, or uncontrolled heart failure, as the vasodilatory effect may worsen these conditions.